secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001628280-24-008339
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics enters collaboration with Merck KGaA for two protein degraders; $16M upfront, up to $740M milestones
--------------------------------------------------------------------------------

- Upfront payment of $16 million from Merck KGaA; Merck to fund discovery research costs.
- C4T eligible for up to approximately $740 million in discovery, regulatory, and commercial milestone payments.
- Tiered royalties on net sales: mid-single to low-double digit percent.
- Collaboration on two targeted protein degraders from C4T's internal oncology pipeline.
- Merck KGaA responsible for clinical development and commercialization; C4T uses TORPEDO platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024008339/0001628280-24-008339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024008339/cccc-20240304.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-008339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer